迈得医疗2025年三季报显示，前三季度公司主营收入2.25亿元，同比上升2.31%；归母净利润883.67万 元，同比上升15.82%；扣非净利润-127.85万元，同比下降526.58%；其中2025年第三季度，公司单季度 主营收入8364.3万元，同比上升54.38%；单季度归母净利润279.16万元，同比上升224.07%；单季度扣 非净利润123.64万元，同比上升118.23%；负债率29.86%，投资收益16.76万元，财务费用-52.36万元， 毛利率40.19%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公告中解释本次业绩变动的原因为： 2025年度,公司整体营业收入实现大幅增长,主要系公司统筹推进生产计划有序落地,保障了产品有效交付, 并且坚持技术创新与工艺迭代双轮驱动,持续强化产品竞争力与市场影响力,血液净化类和药械组合类智 能装备业务发展良好,尤其得益于药械组合类医用耗材在终端市场展现出良好的需求增长态势,对应药械 组合类智能装备市场需求前景乐观,公司重点围绕药械组合类智能装备展开新产品研发和市场开拓, ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301363 | 美好医疗 | 32.18 | -5.46% | 18.03万 | 5.96 Z | | 301093 | 不是股份 | 79.99 | -5.17% | 9.73万 | · 7.87亿 | | 688351 | 微电生理 | 24.55 | -5.10% | 9.77万 | 2.43 Z | | 688029 | 南微医学 | 81.25 | -4.96% | 4.46万 | 3.64亿 | | 300753 | 爰朋医疗 | 33.75 | -4.74% | 11.59万 | 3.94亿 | | 688068 | 热景生物 | 147.44 | -4.65% | 2.75万 | 4.05 Z | | 688217 | 睿昂基因 | 31.14 | -4.45% | 1.98万 | 6293.79万 | | 300246 | 宝莱特 | 13.79 | -4.44% | 18.01万 | 2.50亿 | | 688393 | 安必 ...

Group 1 - The article highlights the successful implementation of the world's first robot-assisted dual Augment (Footing) hip acetabular repair total hip replacement surgery by the orthopedic team at Hong Kong's Alice Ho Miu Ling Nethersole Hospital, led by Dr. Cai Zilong [1][3] - The surgery utilized the Kuntuo orthopedic surgical robot, which was developed by Yuanhua Intelligent, to address a complex case involving severe bone defects in the acetabulum, marking a significant breakthrough in robot-assisted orthopedic surgery for challenging joint reconstruction [1][3] - The innovative "Footing prosthesis" reconstruction plan was introduced, which significantly improves bone coverage and restores the center of joint rotation to its physiological position, fundamentally ensuring the long-term survival rate of the prosthesis [3][7] Group 2 - The patient was an elderly individual suffering from severe hip joint pain and functional impairment, with imaging revealing rare dual-region bone defects in the acetabulum, making traditional surgical methods inadequate [3] - The Kuntuo robot's advanced capabilities in sub-millimeter 3D reconstruction, intelligent planning, and real-time navigation enabled the surgical team to create a customized "Footing prosthesis" by combining two Augment modules, achieving a precise fit [3][7] - The successful surgery is seen as a perfect combination of advanced robotic technology and innovative clinical thinking, providing unprecedented certainty and capability for complex reconstruction surgeries [7] Group 3 - The hospital administration praised the milestone significance of the surgery, stating it opens new treatment pathways for complex hip joint diseases and showcases the hospital's leading strength in integrating cutting-edge medical technology [7] - The Kuntuo robot, which has received approval from the National Medical Products Administration (NMPA), is the world's first five-in-one orthopedic surgical robot, capable of addressing multiple indications including total knee, total hip, unicompartmental, spine, and trauma surgeries [7] - The success of the first "dual Augment" surgery further confirms the robot's strong adaptability and clinical value in complex orthopedic scenarios, injecting strong momentum for Chinese original high-end medical equipment to enter the global stage [7]

21世纪经济报道记者韩利明 为整治政府采购领域"内卷式"竞争，财政部日前印发《关于推动解决政府采购异常低价问题的通知》（下称"《通知》"），明 确将耗材使用量大的实验、医疗等仪器设备采购项目纳入重点管理范畴，从采购需求、审查范围、履约流程等维度划定监管红 线。 事实上，早在2024年12月，财政部便已印发试点通知，在北京、天津、上海、福建、广东自由贸易试验区和海南自由贸易港开 展异常低价问题试点工作；江西省也在2025年12月出台专项工作通知，推动政府采购从"低价导向"向"优质优价"转变。 在业内看来，医疗设备市场因政府采购占比高，近两年伴随行业竞争加剧，细分领域价格内卷现象愈发突出。此次《通知》的 落地实施，将进一步完善政府采购监管机制，引导行业从"价格战"转向理性竞价、良性竞争的轨道。 北京中医药大学卫生健康法学教授、博士生导师邓勇向21世纪经济报道记者指出，新规通过价格红线、全流程审查和履约监 管，从根源上遏制医疗设备领域的异常低价竞争。 "企业需从价格战转向技术+服务+合规的综合竞争，医院需建立全生命周期成本理念，监管部门需压实各方责任，共同推动行业 向优质优价转型。"邓勇教授表示，"行业洗牌不可避免 ...

Group 1 - The core viewpoint of the news is that the recent outbreak of Nipah virus in West Bengal, India, has led to a surge in stock prices of companies involved in nucleic acid and antigen testing in the A-share market, indicating a potential investment opportunity in the healthcare sector [1] - Companies such as Maike Biological (300463.SZ), Zhijiang Biological (688317.SH), and Kaipu Biological (300639.SZ) saw their stock prices hit the daily limit, while others like Wanfu Biological (300482.SZ) and Dongfang Biological (688298.SH) increased by over 10% [1] - The Nipah virus poses a significant health threat with a mortality rate exceeding 40%, and the current situation has raised concerns about the potential for human-to-human transmission, although experts suggest the risk remains low in China [2][3] Group 2 - Nipah virus is classified as a zoonotic disease and has been identified as a priority pathogen by the World Health Organization, highlighting its importance for public health and the potential economic impact on related industries [2] - The virus was first discovered in Malaysia in 1998 and has since caused outbreaks in several countries, leading to significant health and economic consequences, particularly in the pig farming industry [2] - There is currently no specific vaccine or effective treatment for Nipah virus, which relies on supportive care for management, indicating a potential market for future pharmaceutical developments [2]

Market Overview - On January 26, the A-share market experienced slight fluctuations after reaching resistance at 4160 points, with the Shanghai Composite Index closing at 4132.61 points, down 0.09%[7] - The total trading volume for both markets was 32,810 billion yuan, above the median of the past three years[3] Sector Performance - Financial, pharmaceutical, non-ferrous metals, and petroleum sectors performed well, while aerospace, electronic chemicals, computer equipment, and semiconductors lagged[3] - Over 60% of stocks in the two markets declined, with non-ferrous metals and precious metals leading the gains, while aerospace and semiconductor sectors saw significant outflows[7] Valuation Metrics - The average price-to-earnings (P/E) ratios for the Shanghai Composite and ChiNext indices were 16.91 times and 54.02 times, respectively, above the median levels of the past three years, indicating a suitable environment for medium to long-term investments[3][13] Investment Strategy - Investors are advised to adopt a balanced allocation strategy, focusing on AI, high-end manufacturing, and cyclical sectors, as well as resource and consumer sectors for future investment opportunities[3] - Short-term investment opportunities are recommended in the financial, pharmaceutical, petroleum, and coal industries[3] Risk Factors - Potential risks include unexpected overseas economic downturns, domestic policy changes, and macroeconomic disturbances that could impact recovery[4]

迈得医疗(688310.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净利润与上年同期(法 定披露数据)相比，将实现扭亏为盈，实现归属于母公司所有者的净利润6652.13万元左右。 ...

智通财经APP讯，迈得医疗(688310.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净 利润与上年同期(法定披露数据)相比，将实现扭亏为盈，实现归属于母公司所有者的净利润6652.13万元 左右。 ...

Core Viewpoint - The company, Bohui Innovation, has recently received a medical device registration certificate from the National Medical Products Administration of China for its reproductive tract pathogen nucleic acid detection kit, enhancing its product offerings and competitive edge, although sales remain uncertain [1] Group 1: Product Details - The product is a five-pathogen nucleic acid detection kit (PCR - fluorescence probe method) classified as Class III medical device [1] - The registration number is 国械注准 20263400155, with a validity period from January 23, 2026, to January 22, 2031 [1] Group 2: Market Implications - The certification enriches the company's product variety, potentially improving its market competitiveness [1] - However, there is uncertainty regarding the sales performance of the newly certified product [1]

人民财讯1月26日电，迈得医疗(688310)1月26日公告，经财务部门初步测算，预计公司2025年度实现营 业收入4.47亿元左右，与上年同期(法定披露数据)相比，同比增加62.81%左右。预计2025年度实现归属 于母公司所有者的净利润与上年同期(法定披露数据)相比，将实现扭亏为盈，实现归属于母公司所有者 的净利润6652.13万元左右。 ...